THE PINK PILL – Review by April Neale

She glanced around at the group and wondered, Well, who’s doing something about this?

IN THEIR WORDS

Printers and publishers listed on the side. Mary Kilcline Cody, "A Paler Shade of White" in Lost Times and Untold Tales from the Malay World, NUS Press, 2009 p. 93 Brockville, Ontario's website referring to the owner's home as a tourist attraction A 1900s advertisement, hosted on the website of Rochdale, United Kingdom "A Brief MacKenzie Family History Synopsis" (PDF). Archived (PDF) from the original on 3 March 2016. a PDF file from the Ontario Heritage Foundation A drug aimed at boosting women's sex drive is in a heated FDA-approval battle.

Drug information

May 21, 2014— -- It’s called the “little pink pill,” a tiny tablet that could have a huge impact on treating female sexual dysfunction. If it’s approved, it would become the first drug of its kind on the market. The drug Flibanserin is locked in a heated battle for approval from the U.S. Food and Drug Administration, raising controversial questions about why there are so many sexual enhancement drugs available for men and zero for women. Cindy Whitehead, the founder and COO of Sprout Pharmaceuticals, a Raleigh, North Carolina-based company focused on producing only Flibanserin, has been fighting for FDA approval for the drug for three years.

How can I get more information about Addyi?

“There are 25 approved drugs for some form of male sexual dysfunction, but still a great big zero for the most common form of FSD [female sexual dysfunction],” Whitehead said. “No matter how or why we got here, we're here, and we've got to come up with a solution for it.” Flibanserin is more than curing a weak libido. It’s specifically for treating Hypoactive Sexual Desire Disorder, or HSDD. Gynecologist and sexual health crusader Dr. Lauren Streicher explained that HSDD goes much deeper than just a low sex drive. As the old adage goes, if you want something done right—or, in the case of women’s sexual health, at all—you gotta do it yourself.

A self-proclaimed science nerd, Cindy was drawn to the field of sexual health because it was a relatively new concept, ripe for discovery.

Overdose/Missed Dose

“I felt like even though we were close and having a great relationship there was something that wasn't extremely gratifying,” Parrish said. “There was something just not there, so I was in search of something that would make that happen.” Feeling pressure to be a so-called “wholesome soccer mom,” Parrish said she never discussed the issue with her friends but had a feeling she wasn’t alone. A David and Goliath battle to win FDA approval for a drug that boosts a woman’s sexual desire, much as Viagra helps men overcome erectile dysfunction, is captured in the trailer for Aisling Chin-Yee’s documentary The Pink Pill: Sex, Drugs & Who Has Control, which dropped on Thursday. “How do you take on the government for women’s sexual pleasure? You lean right into it and say, ‘This is the conversation we’re going to have,’” says Cindy Eckert, whose Sprout Pharmaceuticals fought a campaign to bring to market Addyi, dubbed “female Viagra” by the media, at one point in the teaser.

How should I store Addyi?

For her efforts, Eckert faced regulatory roadblocks, restrictions and public attacks. The Pink Pill, produced by Julie Bristow of Catalyst and Abby Greensfelder of Everywoman Studios, will have a world fildena 100mg premiere at DOC NYC on Nov. 15. Before that, Sphere Abacus, handling global sales, will shop the film to U.S. and other international buyers at MIPCOM next week.

What is Addyi used for?

And Paramount+ will release the documentary in Canada in early 2026. Eckert’s ultimate victory in securing regulatory approval for Addyi underpins the documentary’s revelations about gender bias at the FDA as a drug that claimed to improve female pleasure was dismissed as trivial or even dangerous. “I am thankful for the trust that I was given by the people I spoke to in the making of this film, and proud to spotlight those who challenge the inequity and systemic bias against women’s and marginalized bodies’ needs, especially in something as fundamental as sexual health,” Chin-Yee said in a statement as she hopes her film sparks a wider conversation about a more equitable healthcare system. The film is executive produced by Bristow, Greensfelder, Chin-Yee, Vibika Bianchi and Knix founder and president Joanna Griffiths, a backer of Docs for Change, a collaboration between Catalyst, the Toronto-based studio, and Knix Fund, the charity arm of the Knix brand. Sign up for THR news straight to your inbox every day Just days after the U.S. Despite the “taboo” nature of her work, she loved that the findings made a real difference in people’s lives.

• Pink pills are sometimes used to address sexual dysfunction in women.
• They are marketed as natural or holistic remedies, depending on ingredients.
• Medical approval varies; some are unregulated, over-the-counter supplements.
• Users should check for FDA approval or medical supervision before use.

“From the moment I stepped into the male sexual health space, my fascination was: This matters in someone’s overall life experience,” she says.

• Pink pills are sometimes associated with the "pink economy" in sexual health.
• They are popular among women seeking discreet, quick solutions.
• Not all pink pills are evidence-based; some rely heavily on marketing claims.
• Consulting a healthcare professional is essential before starting any supplement.

“Sex is an integral part of the human experience, and when you can improve that for somebody,

it’s the highest reward.” But seeing those images at the conference—and realizing that no one else seemed

How FDA decisions shape access

“[HSDD] is a very specific problem in a woman who doesn’t think about sex, she doesn’t fantasize, she doesn’t desire sex,” Streicher said. “What makes it different is that it’s distressing to her. This has a negative impact on her. She’s worried about it, she’s frustrated.” According to the International Journal of Women’s Health, as many as 1 in 10 women suffer from HSDD. While many doctors agree HSDD is a problem that should be addressed, there are no medical treatment options.

Let’s Get to the Root Cause

Whitehead believes Flibanserin is the solution to solving female sexual dysfunction, but said it’s not accurate to call the drug “female Viagra” because it doesn’t work in the same way that Viagra does for men. “Viagra is a blood-flow issue, a mechanical issue, and Flibanserin works on key chemicals in the brain,” she said. Scientists have known for years that a woman’s most significant sexual organ is actually her brain, which is what makes female desire disorders so hard to treat. Flibanserin is taken daily at bedtime, but it’s not a hormonal supplement. Instead, the pill manipulates certain chemicals in the brain to achieve desire.

As Seen In

To test it in clinical trials, Whitehead said it was important to find women who genuinely suffer from HSDD, and not just boredom. “There's a diagnostic questionnaire that physicians go through, and they really can pretty quickly get to whether or not this is a relationship dynamic or something that's happening biologically,” she said. Amanda Parrish said that’s exactly what she was facing. A mother of four from Nashville, Tenn., Parrish said she used to have a smoldering sex life with her husband, but over time, things cooled off. She said the problem wasn’t with him, but with her. to care—spurred Cindy to ask the “obvious,” she says: How can we have as many as 26 FDA-approved medications for men to lead a more satisfying sex life and not a single one for women? “I knew, based on the data, more women than men actually struggle” with sexual dysfunction.

• The pink pill can improve blood flow, leading to increased arousal.
• It may help with vaginal dryness or discomfort during intimacy.
• Psychological factors, like stress, also influence its effectiveness.
• Combining with counseling or therapy can enhance results.

About half of women—40 to 50 percent—will, at some point in their life, suffer from at least

Why the FDA rejected Addyi twice

Cindy Eckert first learned about hypoactive sexual desire disorder (HSDD)—the most common type of sexual dysfunction in women—while attending a conference as a cofounder of Slate Pharmaceuticals, a male-hormone company. (At the time, Slate’s main drug was a testosterone treatment.) During a presentation, scientists showed brain scan images comparing how women with normal desire and women with HSDD reacted to erotic materials. The condition is described by the American Sexual Health Association as “the absence of sexual fantasies and thoughts, and/or desire for or receptivity to, sexual activity that causes the person distress or difficulties.” Cindy compares HSDD to a light switch in the brain that can essentially shut off libido. The proof was in the pictures: Women with the condition had very little to no activation in the pleasure centers of the brain compared to women with normal desire. “Here it was in black-and-white, but everyone sat there looking at their phones,” Cindy says. one of the four main types of sexual dysfunction: desire disorders, arousal disorders, orgasm disorders, and pain disorders.

The research behind the “pink pill”

Food and Drug Administration approved Addyi — the first prescription drug designed to boost sexual desire in women — Canadian company Valeant Pharmaceuticals announced they would be purchasing drug’s maker, Sprout Pharmaceuticals, for $1 billion. Valeant said that they expect the drug to be available in the United States sometime in the fourth quarter of 2015. The drug is being marketed as the “female viagra” however the two drugs couldn’t be more different. The search for a pill to treat women’s sexual difficulties was pursued and later abandoned by Pfizer, Bayer, and Procter & Gamble, among others. But drugs that act on blood flow, hormones, and other biological functions all proved ineffective.

Liver impairment

Addyi, known generically as flibanserin, is intended to treat women who report emotional stress due to a lack of libido. It’s the first drug that acts on brain chemicals that affect mood and appetite. In comparison, Viagra works by increasing blood flow, relaxing muscles in the penis to allow for a man who is already aroused to experience an erection. Addyi and Viagra, a side-by-side comparison: The FDA previously rejected Addyi in 2010 and 2013, due to lackluster effectiveness and side effects which can include dangerously low blood pressure and fainting, especially when combined with alcohol. The same problems can occur when taking the drug with other commonly prescribed medications, including antifungals used to treat yeast infections.

IN CLINICAL TRIALS1, WOMEN ON ADDYI EXPERIENCED:

Opponents say it’s not worth the side effects. However Even the Score, a lobbying group funded by Sprout and other pharmaceutical companies, began publicizing the lack of drugs for female sexual dysfunction as a women’s rights issue last year. At an FDA meeting in June, more than 30 people called for the drug’s approval, frequently citing the campaign. They vastly outnumbered speakers who spoke in opposition to the drug. Story by CCTV America and the Associated Press.